Embed Size (px)
Citation preview
DISTINGUISHED PANEL OF SPEAKERS
Register at www.imapac.com or email Cecilia at [email protected] or call her at +65 6493 2093
Media Partners:Proudly created and produced by
Why you should attend Vaccine World China 2014?
Learn from 500+ years combined industry experience from 30+ top-notch industry experts and opinion leaders Network with 100+ high level decision makers and key opinion leaders in the vaccine R&D and manufacturing space fromChina and the rest of the worldExchange ideas on newest vaccine development and technologies through 20+ real-life case studies Learn 10+ good manufacturing practices and technologies to meet the highest quality standards for vaccine productionBuild relationships and contacts with 50+ vaccine manufacturers from China in 2 days
4 - 5 September 2014 | Hangzhou | China
100+
20+30+
2
Attendees from vaccinemanufacturers, biotechs, NGOs, regulators & technology companiesWorld class speakers from all over the worldHours of networking timeDays of Intense Knowledge sharing
The ONLY event in China for vaccine research & developmentWith a special focus on science and technological challenges and innovations facing Chinese
and developing country vaccine manufacturers
Dr Jianping Li, CEO,KanwavBiopharmaceuticals,China
Dr Allan Riting Liu, Vice President &Senior Advisor,WanbangBiopharmaceuticals Group,China
Dr Wu Ke, CEO,Bravabio,China
Dr Shou-bai Chao, Sr. Vice President,TechnicalOperations and Manufacturing, MedImmune,USA
Ingmar Hoerr, Founder & CEO,Curevac GmBH,Germany
Professor Philippe Roingeard, Professor,Francois Rabelais University,France
Dr H.Fai Poon, Director of Cell Culture,HisunPharmaceuticals, China
Dr Sharon Chan Head of AERAS,China
Dr John Zeng, Vice President,Shanghai Zerun Biotech Co. Ltd,China
Dr Chen Su, CEO,Chengdu Kanghong BiotechnologyCo. Ltd,China
Dr HansArwidsson, President & CEO,Eurocine Vaccines AB,Sweden
Dr Juine-RueyChen, Head of R&D,AdimmuneCorporation,Taiwan
Dr PriyabrataPattnaik, Director of Worldwide Vaccine Initiative,Merck Millipore,Singapore
Dr Shen Shuo, Chief Scientist,Wuhan Institute of Biological Products,China
Dr VikramParadkar, Senior VP Technical Operations,Biological E Limited,India
Dr Li Xiuling, Director of Viral Vaccine Research,National Vaccine & Serum Institute,China
Dr Pan Hun Rong, Head of R&D,WanbangXiamen Innovax Biotech Co. Ltd,China
Dr Joe Yen-HungChow AssociateInvestigator,National Hygiene Research Institute,Taiwan
Dr Chen Li, Professor,Shanghai Medical School, Fudan University,China
Dr Fangzhong Li, Manager ofPre-clinicalDevelopment,Zhejiang Tianyun Bio-pharmaceutical Co. Ltd (a Novartis company), China
Register beforeandSave up to 600 USD
30 May
1
2014 Gold Sponsor 2013 Sponsors & ExhibitorsDr Jian Gao, Director, State KeyLaboratory of Antibody Research & Development, North ChinaPharmaceuticalCo. Ltd, China
... AND MANY MORE!
Dear friends and colleagues,
It is with my utmost pleasure and honour to welcome you to the Vaccine World China 2014. This is the third time IMAPAC has put together a Vaccine China meeting and the organizers have taken huge effort in putting together more than 25 top speakers in the field, with half of them coming fromChina. The focus of this year’s meeting is on scientific and technological innovations for vaccine production and development in developing countries.
The changing landscape in China’s socio-economics has significantly improved healthcare in China. After Chinese CFDA’s regulatory system was approved by WHO in 2011, China’s vaccine industry started growing rapidly. The immunisation rates for those vaccines included in theExpanded Programme of Immunisation (EPI) have achieved 99% with Chinese government looking into increasing the panel of vaccines required for childhood immunisation, such as IPV, which is currently still largely unavailable in many parts of China. The advent of China’s first pre-qualified vaccine is a welcoming sign as many Chinese manufacturers have since stepped up their production capacity and R&D efforts in the race towards more pre-qualified vaccines. This also implies that China and Chinese manufacturers are now going to take up more regional and also international roles.
As part of the vaccine industry, we have the capabilities of changing the lives of many people whom we have never met. As one of the morefortunate ones, it is our responsibility to reach out to those afflicted by infectious diseases and ill health – especially those from developing countries, in providing effective and affordable vaccines. In particular, with emerging infectious diseases and existing ones which have continued to plague many nations, it is important for us to look into vaccine innovations and production scale-up as well as to improve access to vaccine delivery in developing countries. In order to achieve this goal, we must align and combine our efforts, from wet lab R&D, manufacturing all the way to delivery. We must translate good R&D efforts into quality, efficient and economically viable products which can be produced in huge quantities everywhere.
Vaccine World China 2014 is the definitive venue for receiving first-hand information on the current international status of thevaccine innovations in the industry and China’s vaccine R&D efforts. This conference is not just a place for businesses to forge new
EVENT AT A GLANCE
Chairman’s Letter
Vaccine World China 2014 4 - 5 September 2014 | Hangzhou, China
Register at www.imapac.com or email Cecilia at [email protected] or call her at +65 6493 2093
Main Conference Day 1 Main Conference Day 2
China’s Regional and International Roles in Vaccine Research and Development
Manufacturing Excellence (Roundtable)
Pediatric VaccineDevelopment
Pediatric VaccineDevelopment
Cancer Vaccines: Harnessing the concept
of immunotherapy
Cancer Vaccines: Harnessing the concept
of immunotherapy
2
Morning Refreshment & Networking
Speed Networking
Morning Refreshment
Networking Lunch and Exhibition Visit
Conference Closes
Networking Lunch and Exhibition Visit
ManufacturingExcellence
Novel & Innovative Vaccine Designs, Approaches
and Technology
Influenza Vaccines: Towards a Universal
Flu Vaccine
HIV VaccinesBreakthrough
Vaccine Innovations: Meeting DevelopingCountries’ Needs
Welcome Cocktail
Afternoon Refreshments
Sincerely,
CEO, Kanvax Biopharmaceuticals
Dr Jianping Li
relationships, partnerships and networking, but more importantly,it is also a platform for relatively new and emerging companies andcountries to showcase and share their developments and progress in vaccines.
I am looking forward to seeing all of you. I encourage you to join us and share the excitement of new ideas and limitless possibilities. Come join me in Hangzhou this coming September. Let’s work towards a future of 100% immunisation rates, around the world.excitement of new ideas and limitless possibilities. Come join me in Hangzhou this coming September. Let’s work towards a future of 100% immunisation rates, around the world.
Vaccine World China 2014 4 - 5 September 2014 | Hangzhou, China
CONFERENCE DAY 1 4 SEPTEMBER 2014
Roundtable Discussion 1:
Roundtable Discussion 2:
Invitation to:
China’s Regional and International Roles in Vaccine Research and Development
Using mHealth to increase Immunisation rates: the case of Mozambique
Recombinant human serum albumin in vaccineproduction
The process development challenge of a new vaccine
mRNA platform for influenza vaccine development
The development of H7N9 influenza vaccine inTaiwan and the strategy for universal flu vaccine design against influenza
Changes in vaccine manufacturing: How to improve yield at a lower cost? Quality control of vaccine manufacturing
Maximizing and leveraging on the strength of different companies within and outside of China formanufacturing excellence
Opening Keynote
Chairman’s opening remarks
Chairman’s closing remarks
9:00
17:45
8:00 Registration starts
IMAPAC’s welcome remarks8:55
9:05
10:05
13:30
14:00
11:15
10:35 Speed networking and morning refreshments
12:30 Networking Lunch
9:35
3Register at www.imapac.com or email Cecilia at [email protected] or call her at +65 6493 2093
China’s Regional and International Roles in Vaccine Research and Development
Manufacturing Excellence
Manufacturing Excellence
Novel & Innovative Vaccine Designs, Approaches & Technology
Influenza Vaccines: Alternative Manufacturing Platforms
HIV Vaccines Breakthrough
Invitation to: Dr Yong Hong Ge, General Manager, Chengdu Institute of Biological Products, China
Dr Peter Breitenbach, Head, mHealth, Vodafone, South Africa
Dr Gao Jian, Director, State Key Laboratory of Antibody Re-search and Development, North China Pharmaceutical Group Co. New Drug R&D Co., Ltd., China
Dr Shou-bai Chao, Sr. Vice President, Technical Operations and Manufacturing, MedImmune, USA
Dr Ingmar Hoerr, CEO, Curevac, Germany
Dr Juine-Ruey Chen, Head of R&D, Adimmune Corporation, Taiwan
Rapid capacity expansion through manufacturing excellence
Strategies towards a universal influenza vaccine through a live vaccinia viral vector expressingmultiple H5N1 viral proteins and a IL-15 adjuvant
14:30
Dr Vikram Paradkar, Senior VP Technical Operations,Biological E Limited, India Dr Fangzhong Li, Manager of Pre-clinical Development, Zhejiang
Tianyun Bio-pharmaceutical Co. Ltd (a Novartis company), China
Innovative cell culture process for vaccinemanufacturing: best cell lines for efficient andoptimized manufacturing
Recent advances in the development of novel mucosal adjuvants
Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies &constitute a potential bivalent prophylactic vaccine
Genetically-engineered H7N9 Vaccine: DNA Vaccines for improved immunogenicity:
Adaptive clinical trial designs as innovative testing for identifying promising efficacious vaccinecandidates in the development of HIV vaccines
Stimulating the immune system to produce antibody responses to protect against a wide range of viral strains: A HIV model
New and advanced DNA technologies in engineering vaccines Advantages of genetically-engineered flu vaccines:immunogenicity and safety advantages
15:00
16:45
16:15
Dr Hung Fai Poon, Director of Cell Culture Process,Hisun Pharmaceuticals Co. Ltd., China
Hans Arwidsson, President and CEO, Eurocine Vaccines AB, Sweden
Dr Philippe Roingeard, Professor, Francois Rabelais University, France
Dr Xu Jian Qing, Professor, Shanghai Public HealthClinical Center, China
Dr Wu Ke, CEO, Bravobio, China
Invitation to:
Dr Srinivas Rao, Chief, Translational Research Program,National Institute of Allergy & Infectious Diseases, USA
Invitation to:
Dr Chunlai Jiang, Chief R&D Officer, Changchun BCHT Biotechnology Co., China
Invitation to:
Permanent solutions for persistent infections: therapeutic vaccines
Linking HIV vaccine research with viral immunology: Understanding HIV pathogenesis for HIV vaccine design
17:15
Dr Li Chen, Professor, Shanghai Medical School,Fudan University, China
15:45 Afternoon Coffee Break
17:50 Conference Day 1 Closes | Welcome Cocktail
4Register at www.imapac.com or email Cecilia at [email protected] or call her at +65 6493 2093
Vaccine World China 2014 4 - 5 September 2014 | Hangzhou, China
CONFERENCE DAY 2 5 SEPTEMBER 2014
Trends and challenges in research and development of pediatric vaccines for developing countries
Application of Nephelometry in the Stability Test of Multivalent Pneumococcal Vaccine
Efficacy of a Coxsakievirus A16 vaccine candidate in mouse models
Progress and development of a EV71 vaccine for developing countries
Developing a Vaccine of adnovirus carrying F gene of RSV for preventing lower respiratory infections caused by RSV
Aeras and the Global Effort for New TB Vaccines
Panel Discussion: Bridging the gap between benchside and bedside in vaccine innovations
Understanding public health needs in developing countries for vaccine innovations
Vaccine innovations for emerging disease models and outbreaks in Asia
Case study: characterization and evaluation of the immune responses elicited by a novel humanpapillomavirus (HPV) therapeutic vaccine
How to leverage on the molecular mechanisms ofcancer immunology for rational cancer vaccine design
A dendritic-cell based cancer vaccine for cancer immunotherapy in castrate-resistant prostatecancer patients
The early clinical development of an innovative cancer vaccine targeting solid tumors
A DNA-based therapeutic cervical cancer vaccine which can potentially reverse disease progression
Cancer Vaccines: Are we moving forward?
16:00
8:55 Chairman’s opening remarks
9:00
11:00
9:30
10:00
11:30
12:00
14:00
14:45
15:15
Pediatric Vaccine Development
Pediatric Vaccine Development
Vaccine Innovations: Meeting Developing Countries’ Needs
Cancer Vaccines: Harnessing the conceptof immunotherapy
Cancer Vaccines: Harnessing the conceptof immunotherapy
Dr Kutub Mahmood, Scientific Director,Vaccine Development Global Program, PATH, USA
Dr Li Jianping, CEO, Kanvax Biopharmaceuticals, China
Dr Shen Shuo, Chief Scientist, Wuhan Institute of Biological Products, China
Dr Li Xiuling, Director of Viral Vaccine Research, National Vaccine and Serum Institute, China
Dr Joe Yen-Hung Chow, Associate Investigator, National Health Research Institute, Taiwan
Dr Sharon Chan, Head of AERAS, China
Dr Allan Riting Liu, Vice President & Senior Advisor, Wanbang Biopharmaceutical Group, China
Miss Shanelle Hall, Director of Supply Division, UNICEF
Dr. Ted Bianco, Director, Technology Transfer, Wellcome Trust, United Kingdom
Dr Joe Yen-Hung Chow, Associate Investigator, National Health Research Institute, ChinaDr Sharon Chan, Head of AERAS, ChinaDr Chunlai Jiang, Chief R&D Officer, Changchun BCHT Biotechnology Co., China
Dr Chen Su, CEO, Chengdu Kanghong Biotechnology Co. Ltd, China
Dr John Zeng, Vice President, Shanghai Zerun Biotech Co. Ltd, China
Invitation to:
Mr John H Johnson, President and CEO,Dendrion Corporation, USA
Invitation to:
Dr Gao Bin, Senior Scientist, Institute ofMicrobiology, China
Invitation to:
Dr Joseph Kim, President/CEO/Director, Inovio Pharmaceuticals, USA
Invitation to:
Mr Michael G. Hanna Jr., CEO, Vaccinogen Inc., USA
Invitation to:
12:30 Networking Lunch
16:05 Conference Day 2 Closes
Combination of immunological and androgen-directedapproaches for prostate cancer immunotherapyWhat lessons can we learn from a dendritic-cell basedvaccine: understanding the biology of dendritic cells and their response to adjuvants
Importance of China, its role and strengths in new TB vaccine development
How to accelerate new technology discoveries in the laboratory settings What factors to consider in driving innovations and a diverse R&D portfolio/pipeline What are the hurdles for translating basic research to clinical use and how to overcome them
Which aspects of public health should be considered for vaccine innovations?How can government sector, non-profit organization and profitable organizations work hand-in-hand in accelerating vaccine development for developing countries
Current technologies for vaccine designs during emerging outbreaksWhat are the lessons that we can learn from the diseases outbreaks and evolution of pathogens in developing countries so that we leverage on these information for vaccine innovations
Overview and analysis of current global clinical pipeline for cancer vaccines Challenges that the cancer vaccine industry face - whyproduct R&D is restricted to certain tumor types
Invitation to:
Invitation to:
Invitation to:
Confirmed Moderator
Panelists
Chairman’s closing remarks
Closing Keynote
10:35 Speed networking and morning refreshments
5Register at www.imapac.com or email Cecilia at [email protected] or call her at +65 6493 2093
Vaccine World China 2014 4 - 5 September 2014 | Hangzhou, China
WHY SHOULD YOU SPONSOR?
Vaccine World China 2014 will provide commercial organisations with the opportunity to:
Educate the market about what you offerPosition yourselfs as leaders in your field alongside key industry figuresRaise brand awarenessEnjoy the option of privately arranged meetings andconsultations with selected potential clientsHold face-to-face meetings with your target profile
PLUS! Book early to take advantage of the world-class marketing campaign!
50+ touch points over 9 months20,000+ individual communicationsIntegrated campaign featuring web, social media, email,press releases etcPartnerships with leading international publications & associations
For more information on sponsorship & exhibition opportunities, contact:
Natasha JiandaniBusiness Development Manager+65 6493 [email protected]
Adimmune CorporationAerasBeijing Minhai BiotechnologyBio-ReachBravoBioCelltrionChangchun BCHT BiotechnologyChengdu Institute of BiologicalProductsChengdu KanghongBiopharmaceuticalsGuangdong South China Combined Vaccine DevelopmentJanssen CilagJiangsu Provincial Center for Disease Prevention and ControlKanvax BiopharmaceuticalsKuming Institute of Biological SciencesLanzhou Institute of BiologicalProductsMSD Wellcome Trust Hilleman LabNCPC GeneTech BiotechnologyDevelopmentNovartisPATHPnuvax SL BiopharmaceuticalsSanofi Pasteur BeijingSeajet Scientific IncSeikagaku CorporationShanghai Zerun BiotechnologySichuan Yuanda ShuyangPharmaceuticalTasly Group, ChinaZhejiang Vaccine Bio-pharmaceuticaland many more
Organizations that Previously Attended Vaccine World China 2013
SAMPLE LIST
ATTENDEE PROFILE FOR VACCINE WORLD SUMMIT CHINA 2014
ChinaEuropeUSA
Rest of the World (ROW)Rest of Asia (ROA)Japan & Korea
2013 Sponsors & Exhibitors:
BY GEOGRAPHY
50%
15%
15%
10%
5%5% BY INDUSTRY
Vaccine ManufacturersTechnology VendorsAcademicsAdjuvantsCROs
BY JOB TITLE
23% 72%
6%6% 3%
29%
20%
13%
9%
29%
VPs and Directors of ManufacturingVPs and Directors of R&DCEOs/CSO/CTO/MDSScientists and EngineersOthers
